Navigation Links
Cell Biosciences Announces New Leadership
Date:6/25/2008

PALO ALTO, Calif., June 25 /PRNewswire/ -- Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three important additions to its management team.

Tim Harkness was named President and Chief Executive Officer. From 1998 through 2007, Mr. Harkness was the Chief Financial Officer for Molecular Devices Corporation where he helped build the company into a global leader in life science research tools with over $185 million in revenue before successfully selling the company in 2007. Mr. Harkness brings deep knowledge of worldwide life sciences markets, and is expected to lead the transformation of Cell Biosciences into a mature commercial operation.

Richard Lussier was named Vice President, Sales and International Operations. Mr. Lussier has more than 20 years experience in life science sales and commercial operations, including 13 years in the Applera businesses Applied Biosystems and Celera Genomics. During his tenure at Applera, he served as President and General Manager of their Japanese subsidiary for five years. More recently, Mr. Lussier established the worldwide sales, service, and support organization for Solexa Inc., now part of Illumina Inc.

Also announced was the appointment of Walter Ausserer, Ph.D. as Vice President, Marketing. Dr. Ausserer has more than 15 years experience in the development, sales, and marketing of bioanalytical instrumentation. Most recently, he directed product development at Axela Biosensors, a developer of label-free protein characterization systems. Dr. Ausserer previously held senior product development and marketing positions at Caliper Life Sciences and Dionex Corporation.

"The Cell Biosciences team has developed a truly revolutionary technology for protein characterization that I believe has the potential to significantly impact many areas of biological research," said Mr. Harkness. "I am impressed by the tremendous potential of the Cell Biosciences team and technology, and am very excited about the opportunity to lead the company."

The management team appointments come on the heels of multiple recent placements of the Firefly(TM) 3000 system, Cell Bioscience's flagship product for ultrasensitive detection and characterization of proteins in extremely small biological samples. Cell Biosciences began accepting orders for the Firefly 3000 system in late 2007 as part of an early technology access program for leading cell signaling and translational medicine researchers. Participants in the program receive early access to the Firefly 3000 system, which provides unprecedented levels of sensitivity for the analysis of precious samples, such as tissue biopsies, fine-needle tumor aspirates, and stem cells.

To fuel its commercial expansion, the company closed a Series B financing round of $27 million in late 2006, with participation from the Wellcome Trust, Domain Associates, Latterell Venture Partners, Novo Ventures, Posco BioVentures, Mitsui & Co. Venture Partners, RBC Capital Partners and The Vertical Group.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection of specific proteins in extremely small biological samples. The company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA. http://www.cellbiosciences.com

For additional information, please contact Walter Ausserer, Vice President, Marketing, Cell Biosciences, Inc. 650 859-1485.


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL
2. LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting
3. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
4. LI-COR Biosciences Introduces Near-Infrared Small Animal Imager
5. Craig Johnson Joins Ardea Biosciences Board of Directors
6. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
7. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
8. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
9. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
10. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
11. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):